|drug2804||Recombinant Interferon Alfa-2b Wiki||1.00|
|drug991||Data collection Wiki||0.45|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The purpose of this study is to define seroprevalence of anti-SARS-CoV2 among children of Hospital Workers in APHP, particularly exposed population, according to parents' SARS-CoV2 serological status.
Description: Percentage of children with seropositive according to parents' SARS Cov2 serological statusMeasure: Seroprevalence of antibodies anti- SARS Cov2 in children of Hospital workers Time: at inclusion
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports